NEW YORK CITY, NY / ACCESS Newswire / October 7, 2026 / Liquidia Corporation (NASDAQ:LQDA) shares fell roughly 57% after a court ruled that Yutrepia infringes two valid claims of United Therapeutics' '327 patent. If you held LQDA when the ruling hit and lost money, you may have legal rights. Shareholders who suffered losses are encouraged to submit their loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Levi & Korsinsky is investigating potential securities law violations, including whether Liquidia may not have adequately disclosed the risks tied to the '327 patent case. Trial was held in June 2025. The court found two of the six asserted claims valid and infringed. United Therapeutics sought an injunction. The ruling also raised the risk of remedies including removal of Yutrepia's PH-ILD indication and broader restrictions on product availability.
The dollar exposure is specific. Liquidia reported $300.3 million in Yutrepia sales for the first six months of 2026, including approximately $129.9 million in the first quarter. Its Q2 2026 Form 10-Q listed approximately $69.1 million in non-cancelable manufacturing and supply commitments. CEO Roger Jeffs said the Company disagreed with the decision and would pursue appellate options.
Lost money on Liquidia after the Yutrepia patent ruling? Start your loss review here or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the LQDA Investigation
Q: Who is conducting the LQDA investigation?
A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased LQDA securities. The firm is nationally recognized, has ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Who is eligible to participate in the LQDA investigation?
A: Investors who purchased Liquidia Corporation (NASDAQ:LQDA) stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did LQDA stock drop?
A: Shares fell approximately 57% after a court found that Yutrepia infringed two of the six asserted claims of United Therapeutics' '327 patent and that those claims were valid. Investors who purchased LQDA shares and suffered losses may be eligible to seek compensation.
Q: What do LQDA investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?
A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any later sale dates and prices.
Q: What if I already sold my LQDA shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought LQDA and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and find out whether you may be eligible to recover. If you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony?
A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP